Cell line · CVCL_1893
Papers39
1 to 20 of 39
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TUBG1 in RB1-negative tumors. | FASEB J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven Cytostasis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. | Commun Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| In vivo CRISPR screening directly targeting testicular cells. | Cell Genom | 2024 | Its Methods give the RRID and name the line | PubMed | |
New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting the activation of MAPK (ERK1/2) in stressed Müller cells prevents photoreceptor degeneration. | Theranostics | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Retinoschisin and novel Na/K-ATPase interaction partners Kv2.1 and Kv8.2 define a growing protein complex at the inner segments of mammalian photoreceptors. | Cell Mol Life Sci | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism. | BMC Ophthalmol | 2020 | Cellosaurus cites it | PubMed | |
| Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy. | Cell Death Discov | 2020 | Cellosaurus cites it | PubMed | |
| Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines. | Exp Cell Res | 2019 | Cellosaurus cites it | PubMed | |
| Evaluation of cell doubling time in C6 and Y79 cell lines based on seeding density. | 2019 | Cellosaurus cites it | DOI | ||
| Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines. | Oncol Rep | 2018 | Cellosaurus cites it | PubMed | |
| In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line. | BMC Cancer | 2017 | Cellosaurus cites it | PubMed | |
| Generation of etoposide-resistant subline of human retinoblastoma Y79 cells and preliminary study of its resistance mechanism. | 2017 | Cellosaurus cites it | DOI | ||
| A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression. | PLoS One | 2016 | Cellosaurus cites it | PubMed | |
| Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors. | PLoS One | 2016 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1893/papers